Liver Diseases
Welcome,         Profile    Billing    Logout  
 309 Companies   473 Products   473 Products   224 Mechanisms of Action   25 Trials   4900 News 


«12...345678910111213...9899»
  • ||||||||||  paracetamol / Generic mfg.
    Enrollment change, Trial withdrawal, Trial primary completion date:  The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients (clinicaltrials.gov) -  Mar 30, 2017   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Mar 2015
  • ||||||||||  grazoprevir (MK-5172) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
    Trial primary completion date:  Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na (clinicaltrials.gov) -  Mar 30, 2017   
    P2,  N=368, Completed, 
    N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Mar 2015 Trial primary completion date: Mar 2015 --> Jan 2013
  • ||||||||||  Pegasys (pegylated interferon α -2a) / Roche, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
    Trial completion, Enrollment change, Trial primary completion date:  DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (clinicaltrials.gov) -  Mar 29, 2017   
    P4,  N=14, Completed, 
    Trial primary completion date: Jun 2016 --> Jun 2018 Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Jun 2015 --> Nov 2015
  • ||||||||||  paracetamol / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Trial primary completion date:  A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation (clinicaltrials.gov) -  Mar 28, 2017   
    P=N/A,  N=3000, Active, not recruiting, 
    Terminated --> Completed Trial primary completion date: Jan 2017 --> May 2015
  • ||||||||||  Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
    Trial completion:  Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths (clinicaltrials.gov) -  Mar 28, 2017   
    P2,  N=123, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2018 --> Sep 2016 Active, not recruiting --> Completed
  • ||||||||||  Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
    Trial completion:  Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth (clinicaltrials.gov) -  Mar 28, 2017   
    P4,  N=371, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  sorafenib / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 27, 2017   
    P3,  N=35, Terminated, 
    Trial primary completion date: Jul 2016 --> Dec 2016 N=320 --> 35 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Mar 2017; lack of enrolment
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  High Fructose Corn Syrup (clinicaltrials.gov) -  Mar 27, 2017   
    P=N/A,  N=47, Completed, 
    Active, not recruiting --> Terminated Active, not recruiting --> Completed | N=30 --> 47 | Trial primary completion date: Feb 2017 --> Mar 2016
  • ||||||||||  peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
    Enrollment change, Combination therapy:  DIMENSION: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat na (clinicaltrials.gov) -  Mar 23, 2017   
    P3,  N=453, Completed, 
    Phase classification: P=N/A --> P2/3 | N=86 --> 25 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jul 2013; Missing evidence of the effectiveness of the study medication N=300 --> 453
  • ||||||||||  Trial completion, Enrollment change:  Dose Escalation Study for Primary Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 22, 2017   
    P1/2,  N=72, Completed, 
    N=300 --> 453 Active, not recruiting --> Completed | N=60 --> 72
  • ||||||||||  tenofovir disoproxil fumarate / Generic mfg.
    Enrollment closed:  EMRP36100N: Tenofovir in Chronic Hepatitis B With Mild ALT Elevation (clinicaltrials.gov) -  Mar 21, 2017   
    P4,  N=160, Active, not recruiting, 
    Active, not recruiting --> Completed | N=60 --> 72 Recruiting --> Active, not recruiting
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Enrollment closed, Trial primary completion date:  ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov) -  Mar 20, 2017   
    P=N/A,  N=440, Active, not recruiting, 
    Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2022
  • ||||||||||  avadomide (CC-122) / BMS
    Enrollment change, Trial termination, Trial primary completion date, Combination therapy:  Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer (clinicaltrials.gov) -  Mar 20, 2017   
    P1b,  N=12, Terminated, 
    N=40 --> 12 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2016; Slow enrollment and business decision. No safety concerns were identified for the study drugs.
  • ||||||||||  Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, Victrelis (boceprevir) / Roche, Merck (MSD)
    Trial completion, Enrollment change, Trial primary completion date, HEOR:  Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir (clinicaltrials.gov) -  Mar 15, 2017   
    P=N/A,  N=50, Completed, 
    No safety concerns were identified for the study drugs. Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Sep 2014 --> Apr 2013
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  AEMD-IDE-20: Safety Study of the Aethlon Hemopurifier (clinicaltrials.gov) -  Mar 14, 2017   
    P=N/A,  N=8, Terminated, 
    Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Sep 2014 --> Apr 2013 N=10 --> 8 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2017; Adequate safety data has been accumulated and the # of patients meeting inclusion criteria has diminished.
  • ||||||||||  DC Bead (E7040) / Eisai, Boston Scientific
    Trial completion, Trial primary completion date:  DEBDOX: Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 13, 2017   
    P2,  N=24, Completed, 
    N=10 --> 8 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2017; Adequate safety data has been accumulated and the # of patients meeting inclusion criteria has diminished. Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2015
  • ||||||||||  Phase classification:  Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025 (clinicaltrials.gov) -  Feb 28, 2017   
    P=N/A,  N=337, Completed, 
    Trial primary completion date: Oct 2016 --> Apr 2017 Phase classification: P4 --> P=N/A
  • ||||||||||  oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
    Enrollment open, Trial initiation date, Trial primary completion date:  Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis (clinicaltrials.gov) -  Feb 17, 2017   
    P2,  N=32, Recruiting, 
    Trial primary completion date: Dec 2015 --> Dec 2017 Active, not recruiting --> Recruiting | Initiation date: May 2013 --> Jul 2012 | Trial primary completion date: May 2016 --> May 2017
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial completion, Trial primary completion date, Metastases:  Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 11, 2017   
    P2,  N=45, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Mar 2016